


In the Claims:

1. (Currently Amended) A compound of formula I



wherein

R¹ is -O-R⁴ or -N(R⁵)(R⁶);

R² is alkyl or amino;

R³ is hydrogen, alkyl or halogen;

R⁴ is hydrogen,

alkyl,

alkoxyalkyl,

hydroxyalkyl,

aralkyl,

aralkyl which is substituted on the aryl with one or more substituents independently selected

from halogen, trifluoromethyl, amino, alkyl, alkoxy, alkylcarbonyl, cyano, carbamoyl,

alkoxycarbamoyl, methylenedioxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkyaminocarbonyl,

dialkylaminocarbonyl, and hydroxy,

heterocyclalkyl,

heterocyclalkyl ~~heterocyclalkyl~~ which is substituted on one or more carbon atoms of the

heterocyclyl by one or more substituents independently selected from halogen, alkyl, alkoxy, oxo,

cyano; and haloalkyl,

cycloalkylalkyl,

amino-SO₂-; or

alkyl-SO₂-;

R⁵ and R⁶ are independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkylcarbonyl, cycloalkylcarbonyl, aryl, aryl which is substituted with one or more substituents independently selected from halogen, trifluoromethyl, amino, alkyl, alkoxy, alkylcarbonyl, cyano, carbamoyl, alkoxycarbamoyl, methylenedioxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkyaminocarbonyl, dialkylaminocarbonyl, hydroxy and nitro; aralkyl, substituted aralkyl, arylcarbonyl, substituted arylcarbonyl, alkoxyalkyl, hydroxyalkyl, heterocyclyl, heterocyclyl ~~heterocycl~~ which is substituted on one or more carbon atoms by one or more substituents independently selected from halogen, alkyl, alkoxy, oxo, cyano and haloalkyl; heterocyclylalkyl, substituted heterocyclylalkyl, heterocyclylcarbonyl, substituted heterocyclylcarbonyl, alkyl-SO₂-, aryl-SO₂-, heterocyclyl-SO₂-, substituted heterocyclyl-SO₂, or amino-SO₂-, wherein substituted heterocyclylalkyl, substituted heterocyclylcarbonyl, and heterocyclyl-SO₂ are each substituted on one or more carbon atoms of the heterocyclyl by one or more substituents independently selected from halogen, alkyl, alkoxy, oxo, cyano and haloalkyl, and wherein substituted aralkyl and substituted arylcarbonyl are each substituted on the aryl with one or more substituents independently selected from halogen, trifluoromethyl, amino, alkyl, alkoxy, alkylcarbonyl, cyano, carbamoyl, alkoxycarbamoyl, methylenedioxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkyaminocarbonyl, dialkylaminocarbonyl, hydroxy and nitro, or R⁵ and R⁶ together with the N atom to which they are attached form a 5- to 10- membered unsubstituted or substituted heterocyclic ring which optionally comprises a second heteroatom selected from nitrogen or oxygen and, wherein the substituted heterocyclyl ring has one or more substituents independently selected from alkyl and alkoxy;

A is a 5 to 7-membered saturated unsubstituted or substituted heterocyclic ring comprising the nitrogen atom which is attached to the quinazoline ring and optionally a second heteroatom which is selected from oxygen, sulfur or nitrogen and, wherein the ring A substituted heterocyclic ring has one or more substituents independently selected from halogen, alkyl, alkoxy, haloalkoxy, cycloalkylalkoxy, hydroxy, amino, acetylamino, cyano, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl and cycloalkylalkoxyalkyl; and pharmaceutically acceptable salts and esters thereof.

2. (Original) The compound according to claim 1, wherein R² is alkyl.

3. (Original) The compound according to claim 2, wherein R^2 is methyl.
4. (Original) The compound according to claim 1, wherein R^3 is hydrogen.
5. (Original) The compound according to claim 1, wherein R^1 is $-O-R^4$.
6. (Original) The compound according to claim 5, wherein R^4 is hydrogen, aralkyl, substituted aralkyl, heterocyclalkyl, substituted heterocyclalkyl or cycloalkylalkyl.
7. (Original) The compound according to claim 6, wherein R^4 is aralkyl which is benzyl, heterocyclalkyl which is pyridinylmethyl, or aralkyl substituted with cyano, fluoro or chloro; or pyridinylmethyl substituted with cyano, fluoro or chloro.
8. (Original) The compound according to claim 1, wherein R^1 is $-N(R^5)(R^6)$.
9. (Original) The compound according to claim 8, wherein R^5 and R^6 are independently selected from hydrogen, alkyl, cycloalkylalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heterocycl, substituted heterocycl, heterocyclcarbonyl or substituted heterocyclcarbonyl.
10. (Original) The compound according to claim 9, wherein R^5 or R^6 is hydrogen and the other one is alkyl, pyridinyl, furanylcarbonyl or pyridinyl.
11. (Original) The compound according to claim 1, wherein A is a 5 membered saturated unsubstituted or substituted heterocyclic ring comprising the nitrogen atom which is attached to the quinazoline ring and, wherein the ring A substituted heterocyclic ring has one or more substituents independently selected from alkoxy, hydroxy or hydroxyalkyl.

12. (Original) The compound according to claim 11, wherein A is pyrrolidinyl or pyrrolidinyl substituted with hydroxymethyl, methoxy or ethoxy.

13. (Original) The compound according to claim 1 selected from
4-(2-Methyl-4-pyrrolidin-1-yl-quinazolin-7-yloxymethyl)-benzonitrile;
7-(2-Chloro-pyridin-3-ylmethoxy)-2-methyl-4-pyrrolidin-1-yl-quinazoline;
7-(2-Fluoro-pyridin-3-ylmethoxy)-2-methyl-4-pyrrolidin-1-yl-quinazoline;
(S)-{1-[7-(2-Chloro-pyridin-3-ylmethoxy)-2-methyl-quinazolin-4-yl]-pyrrolidin-2-yl}-methanol;
(S)-4-[4-(3-Ethoxy-pyrrolidin-1-yl)-2-methyl-quinazolin-7-yloxymethyl]-benzonitrile;
Isobutyl-(2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-amine;
(2-Methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-pyridin-3-yl-amine;
Furan-2-carboxylic acid (2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-amide;
(S)-[4-(3-Ethoxy-pyrrolidin-1-yl)-2-methyl-quinazolin-7-yl]-pyridin-3-yl-amine; and
(S)-[4-(3-Methoxy-pyrrolidin-1-yl)-2-methyl-quinazolin-7-yl]-pyridin-3-yl-amine.

14. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound in accordance with claim 1 and a pharmaceutically acceptable carrier.

15. (Original) A method of treatment of obesity in a patient in need of such treatment which comprises administering to the patient a therapeutically effective amount of from about 0.1 mg to 20 mg per kg body weight per day of the compound according to claim 1.

16. (Original) A method of treatment of obesity in a patient in need of such treatment which comprises administering to the patient a therapeutically effective amount from about 0.1 mg to 20 mg per kg body weight per day of the compound according to claim 1 and a therapeutically effective amount of from 60 to 720 mg per day of orlistat.

17. (Original) The method according to claim 16 wherein the compound according to claim 1 and the orlistat are administered simultaneously, separately or sequentially.

18. (Original) The pharmaceutical composition of claim 14 further comprising a therapeutically effective amount of orlistat.